Attached files

file filename
EXCEL - IDEA: XBRL DOCUMENT - NUTRA PHARMA CORPFinancial_Report.xls
XML - IDEA: XBRL DOCUMENT - NUTRA PHARMA CORPR8.htm
XML - IDEA: XBRL DOCUMENT - NUTRA PHARMA CORPR3.htm
XML - IDEA: XBRL DOCUMENT - NUTRA PHARMA CORPR6.htm
XML - IDEA: XBRL DOCUMENT - NUTRA PHARMA CORPR1.htm
XML - IDEA: XBRL DOCUMENT - NUTRA PHARMA CORPR7.htm
XML - IDEA: XBRL DOCUMENT - NUTRA PHARMA CORPR4.htm
XML - IDEA: XBRL DOCUMENT - NUTRA PHARMA CORPR5.htm
XML - IDEA: XBRL DOCUMENT - NUTRA PHARMA CORPR9.htm
XML - IDEA: XBRL DOCUMENT - NUTRA PHARMA CORPR2.htm
XML - IDEA: XBRL DOCUMENT - NUTRA PHARMA CORPR14.htm
XML - IDEA: XBRL DOCUMENT - NUTRA PHARMA CORPR12.htm
XML - IDEA: XBRL DOCUMENT - NUTRA PHARMA CORPR17.htm
XML - IDEA: XBRL DOCUMENT - NUTRA PHARMA CORPR15.htm
XML - IDEA: XBRL DOCUMENT - NUTRA PHARMA CORPR10.htm
XML - IDEA: XBRL DOCUMENT - NUTRA PHARMA CORPR16.htm
XML - IDEA: XBRL DOCUMENT - NUTRA PHARMA CORPR13.htm
XML - IDEA: XBRL DOCUMENT - NUTRA PHARMA CORPR11.htm
EX-31.1 - EXHIBIT 31.1 - NUTRA PHARMA CORPv329157_ex31-1.htm
EX-32.1 - EXHIBIT 32.1 - NUTRA PHARMA CORPv329157_ex32-1.htm

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 10-Q/A

(Amendment No. 1)

 

(Mark One)

 

þ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.

 

For the quarterly period ended March 31, 2012

 

¨ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT

 

For the transition period from _________ to ________

 

Commission file numbers 000-32141

 

NUTRA PHARMA CORP.

(Name of registrant as specified in its charter)

 

California   91-2021600
(State or Other Jurisdiction of Organization)   (IRS Employer Identification Number)

 

  2776 University Drive, Coral Springs, Florida   33065
(Address of principal executive offices)   (Zip Code)

 

(954) 509-0911

(Registrant's telephone number, including area code)

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes¨ No þ

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). 

Yes ¨ No ¨

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company.

 

Large accelerated filer ¨ Accelerated filer ¨
Non-accelerated filer ¨ Smaller reporting company þ

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). 

Yes ¨ No þ

 

The number of shares outstanding of the registrant's common stock, par value $0.001 per share, as of November 9, 2012 there were 522,134,676 shares of common stock.

 

 
 

 

Explanatory Note

 

The purpose of this Amendment No. 1 to Nutra Pharma Corporation's Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2012, filed with the Securities and Exchange Commission on November 21, 2012 (the “Form 10-Q”), is solely to furnish Exhibit 101 to the Form 10-Q in accordance with Rule 405 of Regulation S-T. This report provides the consolidated financial statements and related notes from the Form 10-Q formatted in XBRL (eXtensible Business Reporting Language). No other changes have been made to the Form 10-Q. This Amendment No. 1 to the Form 10-Q speaks as of the original filing date of the Form 10-Q, does not reflect events that may have occurred subsequent to the original filing date, and does not modify or update in any way disclosures made in the original Form 10-Q.

 

Pursuant to Rule 406T of Regulation S-T, the interactive data files on this report hereto are deemed not filed or part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, are deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and otherwise are not subject to liability under those sections.

  

Item 6. Exhibits

 

Exhibit No.   Title
31.1   Certification of Chief Executive Officer and Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
     
32.1   Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
     

101 - Interactive data files pursuant to Rule 405 of Regulation S-T, as follows:

 

101.INS -   XBRL Instance Document
     
101.SCH -   XBRL Taxonomy Extension Schema Document
     
101.CAL -   XBRL Taxonomy Extension Calculation Linkbase Document
     
101.DEF -   XBRL Taxonomy Extension Definition Linkbase Document
     
101.LAB -   XBRL Taxonomy Extension Label Linkbase Document
     
101.PRE -   XBRL Taxonomy Extension Presentation Linkbase Document

 

 

SIGNATURES

 

In accordance with the requirements of the Securities Exchange Act of 1934, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 

NUTRA PHARMA CORP.

Registrant

   
Dated:  November 28, 2012 /s/ Rik J. Deitsch
  Rik J. Deitsch
  Chief Executive Officer/Chief Financial Officer